Tumor hilar proximity may be predictive of recurrence, survival, stage, and grade in patients with renal cell carcinoma
Introduction: Recurrence after nephrectomy for localized renal cell carcinoma (RCC) occurs in up to 30% of patients.This study's aims were twofold: (1) to evaluate whether hilar proximity is associated with disease recurrence, cancer-specific survival (CSS), and overall survival (OS) as a preoperative variable; and (2) to determine whether it correlates with adverse pathological features such as stage and grade. Methods:The Emory Nephrectomy database was reviewed, including patients 18 years with non-metastatic RCC (T1-4N0M0) undergoing radical nephrectomy from 2000-2022, with 36 months follow-up.Tumor-to-hilum distance was classified as proximal (<1 cm) or peripheral (1 cm).Outcomes included 3-year disease-free survival (DFS), CSS, OS, pathological stage, and grade.Multivariable Cox proportional hazards and logistic regression models adjusted for clinicodemographic variables.Results: Among 837 patients, proximal tumors were independently associated with increased recurrence within 3 years (HR 1.86, 95%CI 1.34-2.58,p<0.001) and reduced CSS (HR 2.04, 95%CI 1.28-3.26,p=0.003), without a significant association with OS.Proximal tumors also carried higher odds of pathological stage T3-4 (OR 7.48, 95%CI 5.13-10.91,p<0.001) and Fuhrman grade 3-4 (OR 2.04, 95%CI 1. 43-2.91, p<0.001) Conclusions: Tumor proximity to the renal hilum was discovered to be associated with higher recurrence risk, reduced CSS, and adverse pathological features.Hilar proximity may serve as both a marker and driver of aggressive disease, warranting incorporation into risk stratification models and surveillance strategies.
Authors
- Valentina Grajales (ORCID: https://orcid.org/0000-0002-1866-6148)
- Shreyas Joshi (ORCID: https://orcid.org/0000-0002-0020-5298)
- Rachel Kaufman (ORCID: https://orcid.org/0000-0002-5437-2323)
- Ernest Morton (ORCID: https://orcid.org/0009-0001-9123-507X)
- V. Master
- Behnam Nabavizadeh (ORCID: https://orcid.org/0000-0003-4378-9243)
- Vivek Narayan (ORCID: https://orcid.org/0000-0002-8205-738X)
- Talia Helman (ORCID: https://orcid.org/0000-0003-4795-9748)
- Reza Lahiji (ORCID: https://orcid.org/0009-0009-3205-3944)
- William Luke (ORCID: https://orcid.org/0009-0005-7258-5022)
- Adam Braunschweig (ORCID: https://orcid.org/0009-0001-6454-3843)
- Lorenzo Storino Ramacciotti
- Mohammad Hajiha
- Nahar Imtiaz
- Susan Mumford
- Reza Nabavizadeh
- Dattatraya Patil
- Kenneth Ogan
Institutions
- Emory University (US)
- Duke University (US)
- Cornell University (US)
- Duke Medical Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Surgical Oncology Insight
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1016/j.soi.2026.100244
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00